Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).

Article  CAS  PubMed  Google Scholar 

Vogelstein, B. & Kinzler, K. W. The multistep nature of cancer. Trends Genet. 9, 138141 (1993).

Article  Google Scholar 

Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).

Article  CAS  PubMed  Google Scholar 

Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).

Article  CAS  PubMed  Google Scholar 

Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819–1830 (2019).

Article  CAS  PubMed  Google Scholar 

Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019).

Article  CAS  PubMed  Google Scholar 

Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44–56 (2019).

Article  CAS  PubMed  Google Scholar 

Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hellmann, M. D. et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33, 843–852.e4 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Banchereau, R. et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat. Commun. 12, 3969 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao, D., Xu, H., Xu, X., Guo, T. & Ge, W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology 8, e1629258 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Ricciuti, B. et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 8, 1160–1168 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Thummalapalli, R. et al. Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 20, 4408–4418 (2023).

Article  Google Scholar 

Yarchoan, M. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4, e126908 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Budczies, J. et al. Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. Oncoimmunology 7, e1526613 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Krämer, A. et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 228–246 (2023).

Article  PubMed  Google Scholar 

Ross, J. S. et al. Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design. Oncologist 26, e394–e402 (2021).

Article  CAS  PubMed  Google Scholar 

Bochtler, T. et al. Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. Genes Chromosomes Cancer 61, 551–560 (2022).

Article  CAS  PubMed  Google Scholar 

Gatalica, Z., Xiu, J., Swensen, J. & Vranic, S. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur. J. Cancer 94, 179–186 (2018).

Article  PubMed  Google Scholar 

Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).

Article  CAS  PubMed  Google Scholar 

Pouyiourou, M. et al. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat. Commun. 14, 6761 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krämer, A. et al. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. Lancet 404, 527–539 (2024).

Article  PubMed  Google Scholar 

Gandara, D. R. et al. Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types. J. Clin. Oncol. 41, 2503 (2023).

Article  Google Scholar 

Davis, A. A. et al. Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA). J. Clin. Oncol. 35, e23028 (2017).

Article  Google Scholar 

Gandara, D. R. et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat. Med. 24, 1441–1448 (2018).

Article